


Nifeviroc

Cat. No.:	HY-111069
CAS No.:	934740-33-7
Molecular Formula:	C ₃₃ H ₄₂ N ₄ O ₆
Molecular Weight:	590.71
Target:	CCR; HIV
Pathway:	GPCR/G Protein; Immunology/Inflammation; Anti-infection
Storage:	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 95 mg/mL (160.82 mM; Need ultrasonic)
H₂O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.6929 mL	8.4644 mL	16.9288 mL
	5 mM	0.3386 mL	1.6929 mL	3.3858 mL
	10 mM	0.1693 mL	0.8464 mL	1.6929 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (4.23 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.23 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Nifeviroc is an orally active CCR5 antagonist. Nifeviroc is used for the study of HIV type-1 infection^[1].

IC₅₀ & Target

CCR5

HIV-1

REFERENCES

- [1]. Wei Wu, et al. Determination of nifeviroc, a novel CCR5 antagonist: application to a pharmacokinetic study. J Pharm Biomed Anal. 2011 Nov 1;56(3):637-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA